Regeneron Pharmaceuticals, Inc.
REGN
$638.88
-$3.71-0.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.54% | 0.99% | -1.40% | 1.43% | -2.68% |
| Total Other Revenue | 109.04% | 33.00% | 73.56% | 75.98% | -29.94% |
| Total Revenue | 19.04% | 2.51% | 0.90% | 3.62% | -3.70% |
| Cost of Revenue | 23.51% | 11.79% | 13.28% | 16.17% | 6.51% |
| Gross Profit | 12.57% | -7.62% | -10.23% | -7.67% | -15.44% |
| SG&A Expenses | 2.32% | -2.17% | -7.92% | -16.42% | -8.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.98% | 7.80% | 6.76% | 6.03% | 2.26% |
| Operating Income | 23.31% | -11.86% | -10.76% | -1.68% | -21.94% |
| Income Before Tax | -8.15% | 8.93% | 18.10% | -6.72% | 29.16% |
| Income Tax Expenses | 8.00% | 392.82% | 99.02% | -35.09% | 552.11% |
| Earnings from Continuing Operations | -10.08% | -7.97% | 8.91% | -2.84% | 12.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.08% | -7.97% | 8.91% | -2.84% | 12.01% |
| EBIT | 23.31% | -11.86% | -10.76% | -1.68% | -21.94% |
| EBITDA | 18.76% | -8.93% | -8.70% | -0.34% | -17.68% |
| EPS Basic | -7.74% | -3.76% | 13.64% | -0.07% | 13.16% |
| Normalized Basic EPS | 19.84% | 77.68% | -6.94% | 3.24% | -14.56% |
| EPS Diluted | -7.15% | -2.64% | 18.02% | 3.22% | 15.95% |
| Normalized Diluted EPS | 20.61% | 79.88% | -3.32% | 6.66% | -12.47% |
| Average Basic Shares Outstanding | -2.53% | -4.37% | -4.16% | -2.78% | -1.02% |
| Average Diluted Shares Outstanding | -3.15% | -5.54% | -7.75% | -5.89% | -3.39% |
| Dividend Per Share | 6.82% | -- | -- | -- | -- |
| Payout Ratio | 0.16% | -- | -- | -- | -- |